Articles by Antonio Giordano

86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1
ByBarbara Pistilli,Rachel M. Layman,Giuseppe Curigliano,Massimo Cristofanilli, MD,Robert Wesolowski,Hyo S Han,Antonio Giordano,Igor Gorbatchevsky,Sara A. Hurvitz, MD Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1
BySara A. Hurvitz, MD,Rachel M. Layman,Giuseppe Curigliano,Massimo Cristofanilli, MD,Robert Wesolowski,Hyo S Han,Antonio Giordano,Igor Gorbatchevsky,Barbara Pistilli 
98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1
ByKomal L. Jhaveri,Dejan Juric,Antonio Giordano,Antoine Italiano,Gennaro Daniele,Jordi Rodón,Amita Patnaik, MD,Jorge Bartolomé,Anthony D. Elias, MD,Pamela N. Munster, MD,Patricia Lorusso, DO,Aixa Soyano,Maria de Miguel,Joyce O’Shaughnessy, MD,Robert Wesolowski,Giuseppe Curigliano,Tatiana Hernández,Aurélie Lombard,Shawn T. Estrem,Lin Du,Xiaofan Xu,Alberto J. Montero, MD, MBA, CPHQ 
TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer
ByFrancois Clement Bidard,Michail Ignatiadis,Giuseppe Curigliano,Binghe Xu,Theresa Link,Yoichi Naito,Huiping Li,Madoka Iwase,Mark A. Taylor,Carlos H Barrios,Tomofumi Osako,Kevin Kalinsky, MD, MS,Antonio Giordano,Shom Goel, MD,Libero Santarpia,Jason Quan Gong,Kathrine C. Fernandez,Zhe Zhang,Hope S. Rugo, MD 
104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy
ByKevin Kalinsky, MD, MS,Rachel M. Layman,Antonio Giordano,Toru Mukohara,Yeon Hee Park,Geoffrey J. Lindeman,Giampaolo Bianchini,Alexandre de Nonneville,Véronique Diéras, MD,Sherko Kuemmel,Shusen Wang,Zhiming Shao,Sean Kent,Griffith M. Davis,Meng Li,Mafalda Oliveira 
108 Long-Term Safety and Efficacy of First-Line Next Generation CDK4-Selective Inhibitor Atirmociclib + Letrozole for the Treatment of Patients With HR+/HER2− Metastatic Breast Cancer
ByTimothy A. Yap, MBBS, PhD, FRCP,Manuel Magallanes,Binghe Xu,Diego Lucas Kaen,Ernesto Pablo Korbenfeld,Min Yan,Omar A. Zayas-Villanueva,Carlos Alberto Hernández,Peter Schmid, MD,Michal Mego,Santiago Rafael Bella,Xinhong Wu,Madeena Siddiqui,Cynthia Basu,Jennifer Park,Jason Gong,Antonio Giordano 
27 TIP XMT-1660: A Phase 1b Trial of a B7-H4 Targeted Antibody- Drug Conjugate (ADC) in Breast, Endometrial, and Ovarian Cancers
ByKevin Kalinsky, MD, MS,Alexander Spira, MD, PhD, FACP,Sylvia Adams,Nour Abuhadra,Antonio Giordano,Ritesh Parajuli,Heather Han,Amy Weise,Kate Josephs,Erika P. Hamilton, MD